NASDAQ:IDXX
Idexx Laboratories Inc.
Idexx Laboratories Inc.'s revenue grew 10.4% in fiscal 2025 to $4.3B while operating margin rose to 31.6%, its highest in 10 years. Free cash flow was $1.1B, 24.6% of revenue, and the diluted share count fell 2.7%.Summary generated from Idexx Laboratories Inc.'s SEC filings. Latest annual report filed Feb 20, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$4.3B
Revenue growth+10.4%
Revenue, 5-yr CAGR+9.7%
Gross margin61.8%
Operating margin31.6%
Net margin24.6%
ROIC57.3%
Return on equity66.2%
Debt / equity0.28
Free cash flow$1.1B
FCF margin24.6%
Share count change−2.7%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 3,215 | 3,367 | 3,661 | 3,898 | 4,304 |
| Operating income | 932 | 899 | 1,097 | 1,128 | 1,360 |
| Net income | 745 | 679 | 845 | 888 | 1,059 |
| Free cash flow | 636 | 394 | 773 | 808 | 1,057 |
Recent filings
- 4Insider transaction report
Sep 9, 2026 - 4Insider transaction report
Aug 24, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 4, 2026 - 8-KResults of operations and financial condition
Aug 4, 2026 - 8-KAmendment to articles or bylaws
May 15, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 5, 2026 - 8-KResults of operations and financial condition
May 5, 2026 - DEF 14AProxy statement
Mar 27, 2026